Name /EirGenix, Inc.
Address /No. 101, Lane 169, Kangning Street, Xizhi District, New Taipei City
Name /LEE-CHENG LIU
Title /Founder, President & CEO
Others:biopharmaceutical & CDMO service
EirGenix is a contract development and manufacturing organization to provide high quality and cost-effectiveness service supporting our clients in development, analytical testing, and cGMP manufacturing of biopharmaceuticals from pre-clinical to commercial manufacturing. EirGenix has also been a leader in the development of HER2 breast cancer biosimilars. It has formed a licensing agreement with Sandoz to globally market. EirGenix offers the service and biologics to clients around the world.
EirGenix offers contract services for biologics such as process development, analytical services and current Good Manufacturing Practice (cGMP) production in microbial and mammalian systems. It has helped clients with biological products from pre-clinical development to commercial manufacturing, including aiding in Taiwan’s first Covid-19 vaccine approved for emergency use.
EirGenix has also been a leader in the development of HER2 breast cancer biosimilars. We have formed a licensing agreement with Sandoz to globally market our trastuzumab biosimilar EG12014 It yielded positive results in global phase III clinical trials, and has been submitted to the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) for approval. EirGenix has several HER2 related breast cancer biosimilar in development,.
Name /Shao-Chi (Harry) Cheng
Phone /+886-2-7708-0123 #6802